X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
pseudoprogression (516) 516
index medicus (300) 300
humans (267) 267
oncology (233) 233
glioblastoma (196) 196
male (171) 171
female (167) 167
clinical neurology (166) 166
middle aged (150) 150
radiotherapy (148) 148
magnetic resonance imaging (145) 145
aged (120) 120
radiology, nuclear medicine & medical imaging (120) 120
adult (119) 119
disease progression (119) 119
temozolomide (114) 114
brain neoplasms - pathology (112) 112
gliomas (106) 106
radiation necrosis (97) 97
chemotherapy (91) 91
high-grade gliomas (87) 87
glioma (86) 86
immunotherapy (86) 86
medicine & public health (86) 86
brain neoplasms - therapy (80) 80
glioblastoma multiforme (80) 80
cancer (76) 76
survival (71) 71
tumors (71) 71
radiation (68) 68
surgery (67) 67
malignant glioma (66) 66
neurology (65) 65
brain tumors (64) 64
patients (64) 64
concomitant (63) 63
glioblastoma - pathology (63) 63
retrospective studies (61) 61
treatment outcome (61) 61
brain neoplasms - diagnostic imaging (60) 60
development and progression (60) 60
prognosis (60) 60
brain (59) 59
care and treatment (59) 59
malignant gliomas (59) 59
progression (58) 58
therapy (55) 55
brain neoplasms - radiotherapy (54) 54
magnetic resonance imaging - methods (54) 54
neuroimaging (54) 54
diagnosis (53) 53
radiation therapy (52) 52
glioblastoma - therapy (49) 49
mri (49) 49
young adult (49) 49
positron-emission-tomography (48) 48
brain neoplasms - drug therapy (47) 47
necrosis (47) 47
bevacizumab (46) 46
dacarbazine - analogs & derivatives (46) 46
pseudoresponse (46) 46
radiation-therapy (46) 46
perfusion (45) 45
brain neoplasms - mortality (44) 44
brain-tumors (42) 42
response assessment (41) 41
article (40) 40
glioma - pathology (40) 40
nivolumab (40) 40
metastasis (39) 39
aged, 80 and over (38) 38
neurosciences (38) 38
differentiation (37) 37
recurrence (36) 36
adjuvant temozolomide (35) 35
brain neoplasms - diagnosis (35) 35
brain neoplasms - surgery (34) 34
criteria (34) 34
glioblastoma - mortality (34) 34
follow-up studies (33) 33
newly-diagnosed glioblastoma (33) 33
chemoradiotherapy (32) 32
high-grade glioma (32) 32
neurosurgery (32) 32
nuclear magnetic resonance--nmr (32) 32
pseudo-progression (32) 32
tumor progression (32) 32
survival rate (31) 31
cerebral blood-volume (30) 30
glioblastoma - drug therapy (30) 30
neoplasm recurrence, local - pathology (30) 30
radiology (30) 30
brain-tumor (29) 29
dacarbazine - therapeutic use (29) 29
recurrent glioblastoma (29) 29
adolescent (28) 28
analysis (28) 28
diffusion (28) 28
glioblastoma-multiforme (28) 28
combined modality therapy (27) 27
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (492) 492
French (11) 11
German (6) 6
Spanish (6) 6
Turkish (2) 2
Chinese (1) 1
Hungarian (1) 1
Russian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Frontiers in Neurology, ISSN 1664-2295, 2015, Volume 6
Glioblastoma, the most common malignant primary brain tumor in adults is a devastating diagnosis with an average survival of 14-16 months using the current... 
Imaging techniques | Pseudoprogression | Antiangiogenic therapy | Pseudoresponse | Immunotherapy | Glioblastoma | pseudoprogression | antiangiogenic therapy | imaging techniques | pseudoresponse
Journal Article
Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology, ISSN 0167-8140, 08/2019
Pseudoprogression (PsP) following radiation therapy (RT) for low grade glioma (LGG, WHO grade I and II), including both photon-based intensity-modulated RT... 
Journal Article
Neurosurgery, ISSN 0148-396X, 01/2019, Volume 84, Issue 1, pp. 123 - 131
Abstract BACKGROUND The optimal observation interval after the radiosurgical treatment of a sporadic vestibular schwannoma, prior to salvage intervention, is... 
Gamma Knife | Pseudoprogression | Radiosurgery | Vestibular schwannoma | SURGERY | MANAGEMENT | RESECTION | EXPANSION | CLINICAL NEUROLOGY
Journal Article
AMERICAN JOURNAL OF ROENTGENOLOGY, ISSN 0361-803X, 06/2019, Volume 212, Issue 6, pp. 1177 - 1181
OBJECTIVE. The purpose of this study is to assess the frequency of atypical response patterns in oncology patients treated with the programmed cell death... 
pseudoprogression | CRITERIA | nivolumab | immunotherapy | GUIDELINES | IMMUNE-RELATED RESPONSE | RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING | atypical response
Journal Article
by Just, N
British Journal of Cancer, ISSN 0007-0920, 12/2014, Volume 111, Issue 12, pp. 2205 - 2213
Journal Article
Journal of Thoracic Oncology, ISSN 1556-0864, 2018, Volume 14, Issue 3, pp. 468 - 474
Introduction: Nivolumab is effective in the treatment of previously treated patients with advanced NSCLC. However, its radiological evaluation is challenging... 
PD-L1 | Immune checkpoint inhibitor | Pseudoprogression | PD-1 | Nivolumab | ONCOLOGY | RESPIRATORY SYSTEM | RESPONSE EVALUATION CRITERIA | DOCETAXEL | PROGRESSION
Journal Article
Clinical Cancer Research, ISSN 1078-0432, 01/2019, Volume 25, Issue 2, pp. 552 - 561
Purpose: To quantify the accuracy of amide proton transfer-weighted (APTw) MRI for identifying active glioma after treatment via radiographically guided... 
PSEUDOPROGRESSION | TRANSFER APT | DENTATE NUCLEUS | TUMOR PROGRESSION | ONCOLOGY | RESPONSE ASSESSMENT | RADIATION NECROSIS | CONTRAST | DIFFERENTIATION | HIGH-GRADE GLIOMAS | ENDOGENOUS PROTEIN
Journal Article
Immunotherapy, 07/2019
Pseudoprogression is a unique, uncommon phenomenon that often hints at good prognosis. To date, there has been no report of complete remission after... 
Journal Article
Medicine (United States), ISSN 0025-7974, 03/2017, Volume 96, Issue 11
Journal Article
Anti-Cancer Drugs, ISSN 0959-4973, 10/2019, Volume 30, Issue 9, pp. 953 - 958
In the past decade, tumour flare reaction (TFR) was considered as a new side effect associated with immunomodulatory agents (IMiDs) and as a condition of... 
pseudoprogression | haematological malignancies | cancer | Clinical Reports | tumour flare reaction | immunotherapy
Journal Article
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, ISSN 1619-7070, 03/2015, Volume 42, Issue 3, pp. 386 - 396
Ipilimumab is a newly approved immunotherapeutic agent that has been shown to provide a survival benefit in patients with metastatic melanoma. F-18-FDG PET/CT... 
EORTC criteria | CRITERIA | DIAGNOSIS | Metastatic melanoma | F-18-FDG PET/CT | SOLID TUMORS | Ipilimumab | GUIDELINES | DACARBAZINE | CANCER | CHEMOTHERAPY | PSEUDOPROGRESSION | POSITRON-EMISSION-TOMOGRAPHY | IMMUNE THERAPY | RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING
Journal Article
Neurosurgery, ISSN 0148-396X, 05/2019, Volume 84, Issue 5, pp. 1133 - 1137
BACKGROUND: Glioblastoma (GBM) is the most common malignant brain tumor in adult patients. Tumor recurrence commonly occurs around the resection cavity,... 
MALIGNANT GLIOMA | SURVIVAL | PSEUDOPROGRESSION | Stereotactic radiosurgery | RESECTION | Surgery | Glioblastoma | RESPONSE ASSESSMENT | INTRAOPERATIVE RADIOTHERAPY | MULTIFORME | CLINICAL NEUROLOGY | TEMOZOLOMIDE
Journal Article
Annals of Oncology, ISSN 0923-7534, 10/2018, Volume 29, Issue 10, pp. 2115 - 2120
Abstract Background Immune checkpoint inhibitor therapy has resulted in impressive and durable clinical activity for many cancers including melanoma; however,... 
F-18-FDG PET/CT | IMMUNE-RELATED RESPONSE | melanoma | BRAF | DOCETAXEL | PSEUDOPROGRESSION | POSITRON-EMISSION-TOMOGRAPHY | PEMBROLIZUMAB | ONCOLOGY | immunotherapy | anti-PD-1 therapy | positron emission tomography | NIVOLUMAB | PD-1 | PET | IPILIMUMAB
Journal Article
World Neurosurgery, ISSN 1878-8750, 2013, Volume 80, Issue 5, pp. 657 - 657
Journal Article